Overview

Pioglitazone for Oral Premalignant Lesions

Status:
Terminated

Trial end date:
2014-03-01

Target enrollment:

Participant gender:

Summary

The goal of this clinical research study is to learn how Actos (pioglitazone) may affect oral premalignant lesions (OPLs) and/or the risk of mouth cancer. The safety of this drug will also be studied.

Phase:

Phase 2

Details

Lead Sponsor:

National Cancer Institute (NCI)

Treatments:

Pioglitazone